Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients

Abstract

Background: Many studies have documented the association between venous thromboembolism (VTE) and colorectal cancer (CRC). The Khorana model is a VTE risk assessment model for predicting cancer-associated thrombosis. Type 2 diabetes (T2DM) has also been reported to increase the risk of VTE.Purpose: The aim of this study was to investigate the influence of T2DM on Khorana VTE risk in CRC patients and to explore the relationship between Khorana VTE category and CRC clinicopathological factors.Methods: This analysis included 615 CRC patients (205 with T2DM). Fibrinogen and D-dimer levels were compared within each group. A comparison was made of the proportion of patients in different Khorana VTE risk categories in CRC patients with and without T2DM. The association between Khorana VTE risk category and clinicopathological factors among all the CRC patients was evaluated.Results: Fibrinogen levels of CRC patients with T2DM were significantly higher than those of non-diabetes patients (4.13 ± 1.06 vs 3.94 ± 0.98, p < 0.001

Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis

“…Previous studies have identified DM as a potential risk factor for the development of thromboembolic events such as DVT and PE [16]. DM is thought to contribute to a prothrombotic state by increasing platelet activation, altering coagulation factors, and impairing fibrinolysis [16][17][18]. In addition, DM is often associated with other cardiovascular risk factors, such as obesity, hypertension, and dyslipidemia, which may further increase the risk of thromboembolic events [19].…”

“…In addition, DM is often associated with other cardiovascular risk factors, such as obesity, hypertension, and dyslipidemia, which may further increase the risk of thromboembolic events [19]. Several studies have shown that individuals with DM are at increased risk of developing thromboembolic events [16][17][18][19]. As a result, clinicians need to exercise caution when administering antiangiogenic agents, especially in patients with DM, and maintain good DM control to prevent the development of thromboembolic events.…”